Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cord blood transfusions protect fragile preemies?

NCT ID NCT07636473

Disease control Sponsor: University of Parma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using cord blood, rich in fetal hemoglobin, for transfusions in preterm infants can reduce serious complications like blindness, lung disease, and gut problems. Researchers will compare outcomes in 200 very low birth weight babies who receive either cord blood or standard adult donor blood. The goal is to see if the special properties of cord blood help prevent damage caused by oxygen stress.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cord blood red blood cell transfusion
What this could lead to
If successful, this could offer a safer transfusion option for preterm infants, potentially reducing serious complications like blindness and lung disease.
What could go wrong
This is an early-stage trial with 200 participants, so results may not be conclusive. The intervention is complex and may not show clear benefits over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

24 to 31 weeks

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Preterm neonates born between 24+0 and 31+6 weeks of gestational age; * Requirement for at least one red blood cell transfusion during hospitalization, according to current Italian transfusion thresholds; * Written informed consent obtained from parents or legal guardians prior to any study procedure. Exclusion Criteria: * Gestational age \> 32+0 weeks; * Pregnancy complicated by maternal-fetal alloimmunization (e.g., hemolytic disease of the newborn); * Pregnancy complicated by fetal hydrops; * Major congenital anomalies or genetic syndromes; * Previous red blood cell transfusions (prior to enrollment); * Perinatal hemorrhage at delivery; * Documented congenital infections (TORCH).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia anemia of prematurity bronchopulmonary dysplasia prevention target necrotizing enterocolitis prevention target retinopathy of prematurity prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Prematurity complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.